home / stock / bmkdf / bmkdf quote
Last: | $0.23 |
---|---|
Change Percent: | 4.96% |
Open: | $0.2186 |
Close: | $0.23 |
High: | $0.23 |
Low: | $0.2112 |
Volume: | 6,300 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.23 | $0.2186 | $0.23 | $0.23 | $0.2112 | 6,300 | 04-25-2024 |
$0.2249 | $0.2249 | $0.2249 | $0.2249 | $0.2249 | 336 | 04-24-2024 |
$0.2054 | $0.2163 | $0.2054 | $0.2163 | $0.205 | 38,000 | 04-22-2024 |
$0.2051 | $0.1929 | $0.2051 | $0.2051 | $0.18 | 25,200 | 04-18-2024 |
$0.203 | $0.2064 | $0.203 | $0.2064 | $0.203 | 8,600 | 04-17-2024 |
$0.192 | $0.19324 | $0.192 | $0.19324 | $0.192 | 3,500 | 04-16-2024 |
$0.2037 | $0.20735 | $0.2037 | $0.212 | $0.2037 | 13,600 | 04-11-2024 |
$0.2164 | $0.2181 | $0.2164 | $0.2181 | $0.2164 | 9,000 | 04-10-2024 |
$0.20995 | $0.20995 | $0.20995 | $0.20995 | $0.20995 | 1,000 | 04-09-2024 |
$0.2163 | $0.2163 | $0.2163 | $0.2163 | $0.2163 | 1,500 | 04-08-2024 |
$0.21 | $0.2116 | $0.21 | $0.213 | $0.205 | 15,100 | 04-03-2024 |
$0.224 | $0.23 | $0.224 | $0.23 | $0.224 | 2,500 | 03-26-2024 |
$0.2245 | $0.2245 | $0.2245 | $0.2245 | $0.2245 | 280 | 03-20-2024 |
$0.2135 | $0.2135 | $0.2135 | $0.2135 | $0.2135 | 10,000 | 03-19-2024 |
$0.23 | $0.23 | $0.23 | $0.23 | $0.23 | 13,500 | 03-18-2024 |
$0.216 | $0.2228 | $0.216 | $0.2228 | $0.216 | 3,200 | 03-13-2024 |
$0.2167 | $0.21917 | $0.2167 | $0.21917 | $0.2167 | 17,000 | 03-11-2024 |
$0.2142 | $0.2179 | $0.2142 | $0.2179 | $0.2142 | 1,600 | 03-07-2024 |
$0.216 | $0.216 | $0.216 | $0.216 | $0.216 | 25,000 | 02-28-2024 |
$0.216 | $0.216 | $0.216 | $0.216 | $0.216 | 500 | 02-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
BioMark Diagnostics Inc Company Name:
BMKDF Stock Symbol:
OTCMKTS Market:
BioMark Diagnostics Inc Website:
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that the Company intends...
The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia--(Newsfile Corp. - April 9, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced sta...
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient...